SMER28
25 mg
| 99.97%
TargetMol
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells via an mTOR-independent mechanism and prevented the accumulation of amyloid beta peptide.
More Information
Supplier Page
SMER28
10 mg
| 99.97%
TargetMol
SMER28 is a small-molecule enhancer (SMER) of autophagy, inducing autophagy independently of rapamycin in mammalian cells via an mTOR-independent mechanism and prevented the accumulation of amyloid beta peptide.
More Information
Supplier Page
TargetMol
Spermine is a biogenic polyamine formed from spermidine. It is found in a wide variety of organisms and tissues and is an essential growth factor in some bacteria.
More Information
Supplier Page
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information
Supplier Page
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information
Supplier Page
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information
Supplier Page
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information
Supplier Page
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information
Supplier Page
ALK-IN-1
100 mg
| Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information
Supplier Page
ALK-IN-1
10 mg
| Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information
Supplier Page